Skip to main content
Top
Published in: Virology Journal 1/2007

Open Access 01-12-2007 | Research

Nucleocapsid formation and RNA synthesis of Marburg virus is dependent on two coiled coil motifs in the nucleoprotein

Authors: Andrea DiCarlo, Peggy Möller, Angelika Lander, Larissa Kolesnikova, Stephan Becker

Published in: Virology Journal | Issue 1/2007

Login to get access

Abstract

The nucleoprotein (NP) of Marburg virus (MARV) is responsible for the encapsidation of viral genomic RNA and the formation of the helical nucleocapsid precursors that accumulate in intracellular inclusions in infected cells. To form the large helical MARV nucleocapsid, NP needs to interact with itself and the viral proteins VP30, VP35 and L, which are also part of the MARV nucleocapsid. In the present study, a conserved coiled coil motif in the central part of MARV NP was shown to be an important element for the interactions of NP with itself and VP35, the viral polymerase cofactor. Additionally, the coiled coil motif was essential for the formation of NP-induced intracellular inclusions and for the function of NP in the process of transcription and replication of viral RNA in a minigenome system. Transfer of the coiled coil motif to a reporter protein was sufficient to mediate interaction of the constructed fusion protein with the N-terminus of NP. The coiled coil motif is bipartite, constituted by two coiled coils which are separated by a flexible linker.
Appendix
Available only for authorised users
Literature
1.
go back to reference Martini GA, Kanuff HG, Schmidt HA, Mayer G, Baltzer G: Über eine bisher unbekannte, von Affen übertragene Viruserkrankung: Marburg-VirusKrankheit. Dtsch Med Wochenschr 1968, 93: 559-571.PubMedCrossRef Martini GA, Kanuff HG, Schmidt HA, Mayer G, Baltzer G: Über eine bisher unbekannte, von Affen übertragene Viruserkrankung: Marburg-VirusKrankheit. Dtsch Med Wochenschr 1968, 93: 559-571.PubMedCrossRef
2.
go back to reference Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, Jones SM, Feldmann H: Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006, 367: 1399-1404. 10.1016/S0140-6736(06)68546-2PubMedCrossRef Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, Jones SM, Feldmann H: Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006, 367: 1399-1404. 10.1016/S0140-6736(06)68546-2PubMedCrossRef
3.
go back to reference Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11: 786-790. 10.1038/nm1258PubMedCrossRef Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11: 786-790. 10.1038/nm1258PubMedCrossRef
4.
go back to reference CDC: Outbreak of Marburg Virus Hemorrhagic Fever – Angola, Ocotber 1, 2004-March 29, 2005. MMWR, Morbidity and Mortality Weekly Report 2005., 54: CDC: Outbreak of Marburg Virus Hemorrhagic Fever – Angola, Ocotber 1, 2004-March 29, 2005. MMWR, Morbidity and Mortality Weekly Report 2005., 54:
5.
go back to reference WHO: Marburg haemorrhagic fever in Uganda. Epidemic and Pandemic Alert and Response (EPR) 2007. WHO: Marburg haemorrhagic fever in Uganda. Epidemic and Pandemic Alert and Response (EPR) 2007.
6.
go back to reference Becker S, Rinne C, Hofsäss U, Klenk H-D, Mühlberger E: Interactions of Marburg virus nucleocapsid proteins. Virology 1998, 249: 406-417. 10.1006/viro.1998.9328PubMedCrossRef Becker S, Rinne C, Hofsäss U, Klenk H-D, Mühlberger E: Interactions of Marburg virus nucleocapsid proteins. Virology 1998, 249: 406-417. 10.1006/viro.1998.9328PubMedCrossRef
7.
go back to reference Becker S, Huppertz S, Klenk HD, Feldmann H: The nucleoprotein of Marburg virus is phosphorylated. J Gen Virol 1994,75(Pt 4):809-818.PubMedCrossRef Becker S, Huppertz S, Klenk HD, Feldmann H: The nucleoprotein of Marburg virus is phosphorylated. J Gen Virol 1994,75(Pt 4):809-818.PubMedCrossRef
8.
go back to reference Kolesnikova L, Mühlberger E, Ryabchikova E, Becker S: Ultrastructural organization of recombinant Marburg virus nucleoprotein: comparison with Marburg virus inclusions. J Virol 2000, 74: 3899-3904. 10.1128/JVI.74.8.3899-3904.2000PubMedPubMedCentralCrossRef Kolesnikova L, Mühlberger E, Ryabchikova E, Becker S: Ultrastructural organization of recombinant Marburg virus nucleoprotein: comparison with Marburg virus inclusions. J Virol 2000, 74: 3899-3904. 10.1128/JVI.74.8.3899-3904.2000PubMedPubMedCentralCrossRef
9.
go back to reference Mavrakis M, Kolesnikova L, Schoehn GBS, Ruigrok RWH: Morphology of Marburg virus NP-RNA. Virology 2002, 296: 300-307. 10.1006/viro.2002.1433PubMedCrossRef Mavrakis M, Kolesnikova L, Schoehn GBS, Ruigrok RWH: Morphology of Marburg virus NP-RNA. Virology 2002, 296: 300-307. 10.1006/viro.2002.1433PubMedCrossRef
10.
go back to reference Möller P, Pariente N, Klenk HD, Becker S: Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription. J Virol 2005, 79: 14876-14886. 10.1128/JVI.79.23.14876-14886.2005PubMedPubMedCentralCrossRef Möller P, Pariente N, Klenk HD, Becker S: Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription. J Virol 2005, 79: 14876-14886. 10.1128/JVI.79.23.14876-14886.2005PubMedPubMedCentralCrossRef
11.
go back to reference Mühlberger E, Weik M, Volchkov VE, Klenk H-D, Becker S: Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 1999, 73: 2333-2342.PubMedPubMedCentral Mühlberger E, Weik M, Volchkov VE, Klenk H-D, Becker S: Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 1999, 73: 2333-2342.PubMedPubMedCentral
12.
go back to reference Mühlberger E, Lotfering B, Klenk H-D, Becker S: Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998, 72: 8756-8764.PubMedPubMedCentral Mühlberger E, Lotfering B, Klenk H-D, Becker S: Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998, 72: 8756-8764.PubMedPubMedCentral
13.
go back to reference Schultz DE, Honda M, Whetter LE, McKnight KL, Lemon SM: Mutations within the 5' nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells. J Virol 1996, 70: 1041-1049.PubMedPubMedCentral Schultz DE, Honda M, Whetter LE, McKnight KL, Lemon SM: Mutations within the 5' nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells. J Virol 1996, 70: 1041-1049.PubMedPubMedCentral
14.
go back to reference Hartlieb B, Modrof J, Mühlberger E, Klenk HD, Becker S: Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem 2003, 278: 41830-41836. 10.1074/jbc.M307036200PubMedCrossRef Hartlieb B, Modrof J, Mühlberger E, Klenk HD, Becker S: Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem 2003, 278: 41830-41836. 10.1074/jbc.M307036200PubMedCrossRef
15.
go back to reference Lupas A, Van Dyke M, Stock J: Predicting coiled coils from protein sequences. Science 1991, 252: 1162-1164. 10.1126/science.252.5009.1162PubMedCrossRef Lupas A, Van Dyke M, Stock J: Predicting coiled coils from protein sequences. Science 1991, 252: 1162-1164. 10.1126/science.252.5009.1162PubMedCrossRef
16.
go back to reference Burkhard P, Stetefeld J, Strelkov SV: Coiled coils: a highly versatile protein folding motif. Trends Cell Biol 2001, 11: 82-88. 10.1016/S0962-8924(00)01898-5PubMedCrossRef Burkhard P, Stetefeld J, Strelkov SV: Coiled coils: a highly versatile protein folding motif. Trends Cell Biol 2001, 11: 82-88. 10.1016/S0962-8924(00)01898-5PubMedCrossRef
17.
go back to reference Cohen C, Parry DA: Alpha-helical coiled coils: more facts and better predictions. Science 1994, 263: 488-489. 10.1126/science.8290957PubMedCrossRef Cohen C, Parry DA: Alpha-helical coiled coils: more facts and better predictions. Science 1994, 263: 488-489. 10.1126/science.8290957PubMedCrossRef
18.
go back to reference Alfadhli A, Steel E, Finlay L, Bachinger HP, Barklis E: Hantavirus Nucleocapsid Protein Coiled-Coil Domains. J Biol Chem 2002, 277: 27103-27108. 10.1074/jbc.M203395200PubMedCrossRef Alfadhli A, Steel E, Finlay L, Bachinger HP, Barklis E: Hantavirus Nucleocapsid Protein Coiled-Coil Domains. J Biol Chem 2002, 277: 27103-27108. 10.1074/jbc.M203395200PubMedCrossRef
19.
go back to reference Green TJ, Zhang X, Wertz GW, Luo M: Structure of the vesicular stomatitis virus nucleoprotein-RNA complex. Science 2006, 313: 357-360. 10.1126/science.1126953PubMedCrossRef Green TJ, Zhang X, Wertz GW, Luo M: Structure of the vesicular stomatitis virus nucleoprotein-RNA complex. Science 2006, 313: 357-360. 10.1126/science.1126953PubMedCrossRef
20.
21.
go back to reference Myers TM, Pieters A, Moyer SA: A highly conserved region of the Sendai virus nucleocapsid protein contributes to the NP-NP binding domain. Virology 1997, 229: 322-335. 10.1006/viro.1996.8429PubMedCrossRef Myers TM, Pieters A, Moyer SA: A highly conserved region of the Sendai virus nucleocapsid protein contributes to the NP-NP binding domain. Virology 1997, 229: 322-335. 10.1006/viro.1996.8429PubMedCrossRef
22.
go back to reference Bankamp B, Horikami SM, Thompson PD, Huber M, Billeter M, Moyer SA: Domains of the measles virus N protein required for binding to P protein and self-assembly. Virology 1996, 216: 272-277. 10.1006/viro.1996.0060PubMedCrossRef Bankamp B, Horikami SM, Thompson PD, Huber M, Billeter M, Moyer SA: Domains of the measles virus N protein required for binding to P protein and self-assembly. Virology 1996, 216: 272-277. 10.1006/viro.1996.0060PubMedCrossRef
23.
go back to reference Liston P, Batal R, DiFlumeri C, Briedis DJ: Protein interaction domains of the measles virus nucleocapsid protein (NP). Arch Virol 1997, 142: 305-321. 10.1007/s007050050078PubMedCrossRef Liston P, Batal R, DiFlumeri C, Briedis DJ: Protein interaction domains of the measles virus nucleocapsid protein (NP). Arch Virol 1997, 142: 305-321. 10.1007/s007050050078PubMedCrossRef
Metadata
Title
Nucleocapsid formation and RNA synthesis of Marburg virus is dependent on two coiled coil motifs in the nucleoprotein
Authors
Andrea DiCarlo
Peggy Möller
Angelika Lander
Larissa Kolesnikova
Stephan Becker
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-4-105

Other articles of this Issue 1/2007

Virology Journal 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine